About Pharmerit_WPadmin

This author has not yet filled in any details.
So far Pharmerit_WPadmin has created 218 blog entries.

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada.

Cost-effectiveness analysis of standalone trabecular micro-bypass stents in patients with mild-to-moderate open-angle glaucoma in Canada. Objectives To estimate the cost-utility of two trabecular micro-bypass stents (TBS) implantation versus standard of [...]

2019-01-28T09:28:22+00:00January 28th, 2019|

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China.

Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China. Background and Objective Teriflunomide is a once-daily oral immunomodulatory agent approved in 80 countries for the [...]

2019-01-29T10:49:13+00:00January 28th, 2019|

Deep-vein thrombosis in Europe – Burden of illness in relationship to healthcare resource utilization and return to work.

Deep-vein thrombosis in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Objective Deep-vein thrombosis (DVT) forms a major healthcare burden in Europe, but [...]

2019-01-28T07:33:58+00:00January 22nd, 2019|

Pulmonary embolism in Europe – Burden of illness in relationship to healthcare resource utilization and return to work

Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work. Objective Pulmonary embolism (PE) is associated with a substantial economic burden. However [...]

2019-01-22T09:25:43+00:00January 22nd, 2019|

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States

Cost-Effectiveness of Alemtuzumab in the Treatment of Relapsing Forms of Multiple Sclerosis in the United States Objective To evaluate the cost-effectiveness of alemtuzumab compared with fingolimod, natalizumab, ocrelizumab, and generic [...]

2018-12-14T07:23:51+00:00December 14th, 2018|